The European Medicines Agency (EMEA) has recommended the suspension of the marketing authorisation for Raptiva (efalizumab), from Serono. The EMEA's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Raptiva no longer outweigh its risks, because of safety concerns, including the occurrence of progressive multifocal leukoencephalopathy (PML) in patients taking the medicine.
The U.S. Food and Drug Administration recently approved the injectable drug degarelix, the first new drug in several years for prostate cancer. Degarelix is intended to treat patients with advanced prostate cancer.
Most Read News
- Experts discuss ways to embed patient voices and values in clinical research
- Bristol-Myers Squibb reports first quarter 2013 financial results
- AstraZeneca first quarter results 2013
- Study opens new prospects for developing new targeted therapies for breast cancer
- Bayer: Life Sciences off to a good start in anniversary year
- Cancer studies often lack necessary rigor to answer key questions
- New class of drug targets skin cancer
Company Profiles and News
Showcase your Company Profile / News
Pharmaceutical Companies
News in Pictures
Be on top of World Pharma News!
Advertise with us - Download World Pharma News' Media Pack Read more
Abbott Launches New Psoriasisanswers.com Web site
August marks National Psoriasis Awareness Month, an opportunity to raise awareness about psoriasis, a skin disease that affects nearly 7.5 million Americans. For those living with this condition, finding information Read more
AstraZeneca Headquarters, London
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, Read more
Site Roche Basel
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in Read more
Gehry building, Novartis headquarters in Basel, Switzerland
Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving Read more
GSK Corporate HQ
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better Read more
Sanofi-aventis Group head office
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: Read more
Boehringer Ingelheim Center, Ingelheim, Germany
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 Read more
Novo Nordisk's corporate headquarters in Bagsværd, Denmark
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth Read more
Business & Industry News
- Vortioxetine, a new multimodal agent in development for the treatment of major depression
- AstraZeneca issues update on accelerated oncology pipeline
- GSK and Save the Children form unique partnership to save the lives of one million children
- Novartis drug Ilaris® approved by FDA to treat active systemic juvenile idiopathic arthritis
- Amgen and Zhejiang Beta Pharma announce planned joint venture in China
- Boehringer Ingelheim joins Structural Genomics Consortium
- Real-world data at ARVO highlight transformational outcomes seen with Lucentis®
Research & Development News
- Fish oil supplements may help fight against Type 2 diabetes
- Research offers promising new approach to treatment of lung cancer
- Global recommendations on child medicine
- Breakup of physician, drug company relationship could improve health care, cut cost
- Nanotechnology could help fight diabetes
- First prospective trial shows molecular profiling timely for tailoring therapy
- Breakthrough in how pancreatic cancer cells ingest nutrients points to new drug target
Regulatory Affairs News
- FDA budget requests $4.7 billion
- FDA alerts health care providers of recall of anemia drug Omontys
- FDA approves Pomalyst for advanced multiple myeloma
- FDA approves Gleevec for children with acute lymphoblastic leukemia
- FDA approves new seasonal influenza vaccine made using novel technology
- FDA approves Eliquis to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation
- FDA expands use of Xarelto to treat, reduce recurrence of blood clots